SOURCE: Oxis International, Inc.

June 18, 2015 09:37 ET

Oxis Biotech Inc. Announces Appointment of Dr. Stephen M. Chang to Scientific Advisory Board

TAMPA, FL--(Marketwired - June 18, 2015) - Oxis International, Inc. (OTCQB: OXIS), a biotechnology company focused on cannabinoid therapy development and commercialization, announced today Dr. Stephen M. Chang has joined the Scientific Advisory Board for its wholly owned subsidiary, Oxis Biotech, Inc.

Dr. Stephen M. Chang is Vice President-Research & Development at New York Stem Cell Foundation, Chief Scientific Officer at Stemgent, Inc., and Independent Director at MultiCell Technologies, Inc. Dr. Chang was previously employed as Chief Scientific Officer & Vice President by Canji, Inc., Chief Scientific Officer & Vice President at Schering-Plough Research Institute, and President and Chief Executive Officer at MultiCell Immunotherapeutics, Inc.

He served on the Board of Directors at Histogen, Inc. Dr. Chang received his undergraduate degree from the University of Michigan and a doctorate degree from the University of California, Irvine.

Oxis Chairman and CEO Tony Cataldo, stated, "Dr. Chang brings a wealth of experience with him which will bring tremendous value to our Science Advisory Board. His positions with the NIH (Research) and development of patents while at Schering-Plough Healthcare, Inc. (now Merck (MRK)), will help Oxis and Dr. Xie (see Oxis Press Release) advance our newly acquired P62 Multiple Myeloma platform. We look forward to working with Dr. Chang."

"I am excited to join the SAB and work with the Oxis world class investigators in the area of cancer. The development of therapies for 'Triple Negative Breast Cancer' and 'Multiple Myeloma' using the Oxis drug development platform, represents a win-win situation for patients and their families," said Dr. Chang.

ABOUT OXIS BIOTECH, INC. - OXIS is a biotech company that develops and commercializes innovative drugs of therapeutic molecules including cannabinoids, which are focused on several cancer indications. Oxis address the clinical shortcomings of existing commercial products in related fields. OXIS has formed relationships with some of the world's leading cannabinoid researchers and institutions to advance its technologies.

Forward-Looking Statements Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the payment of dividends, marketing and distribution plans, development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the Company's ability to accomplish its business initiatives, significant fluctuations in marketing expenses and ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company's filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information